IN THE LAST QT. ALONE FUNDS BUYING SRPT HAVE INCREASED 60% posted.
The Insider Monkey 4/3/13
This metric says you are smart to buy SRPT
What does the smart money think about Sarepta Therapeutics Inc (NASDAQ:SRPT)?
At year's end, a total of 16 of the hedge funds we track were long in this stock, a change of 60% from one quarter earlier. With hedge funds' sentiment swirling, there exists a few key hedge fund managers who were increasing their holdings substantially. According to our comprehensive database, Perceptive Advisors, managed by Joseph Edelman, holds the largest position in Sarepta Therapeutics Inc (NASDAQ:SRPT). Perceptive Advisors has a $33 million position in the stock, comprising 5.9% of its 13F portfolio. Sitting at the No. 2 spot is James E. Flynn of Deerfield Management, with a $19 million position; 1.1% of its 13F portfolio is allocated to the stock. Remaining peers that are bullish include Steven Cohen's SAC Capital Advisors, Phill Gross and Robert Atchinson's Adage Capital Management and Joseph Edelman's Perceptive Advisors.